CoChat

The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate

Schüler, Andrea, Schwieger, Maike, Engelmann, Afra, Weber, Kristoffer, Horn, Stefan, Müller, Ursula, Arnold, Michael A., Olson, Eric N., Stocking, Carol · 2008 · Blood
Cited by 70

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Mef2c is a MADS (MCM1-agamous–deficient serum response factor) transcription factor best known for its role in muscle and cardiovascular development. A causal role of up-regulated MEF2C expression in myelomonocytic acute myeloid leukemia (AML) has recently been demonstrated. Due to the pronounced monocytic component observed in Mef2c-induced AML, this study was designed to assess the importance of Mef2c in normal myeloid differentiation. Analysis of bone marrow (BM) cells manipulated to constitutively express Mef2c demonstrated increased monopoiesis at the expense of granulopoiesis, whereas BM isolated from Mef2cΔ/− mice showed reduced levels of monocytic differentiation in response to cytokines. Mechanistic studies showed that loss of Mef2c expression correlated with reduced levels of transcripts encoding c-Jun, but not PU.1, C/EBPα, or JunB transcription factors. Inhibiting Jun expression by short-interfering RNA impaired Mef2c-mediated inhibition of granulocyte development. Moreover, retroviral expression of c-Jun in BM cells promoted monocytic differentiation. The ability of Mef2c to modulate cell-fate decisions between monocyte and granulocyte differentiation, coupled with its functional sensitivity to extracellular stimuli, demonstrate an important role in immunity—and, consistent with findings of other myeloid transcription factors, a target of oncogenic lesions in AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2007-10-116343

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 70

Metadata

Authors
Schüler, A., Schwieger, M., Engelmann, A., Weber, K., Horn, S., Müller, U., Arnold, M. A., Olson, E. N., & Stocking, C.
Venue
Blood
Published
2008-05-01
Volume
111
Issue
9
Pages
4532-4541
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2024919540
Cited by
70
References
30
FWCI
2.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate. https://app.cochat.ai/papers/10.1182/blood-2007-10-116343
The paper
Schüler, A., Schwieger, M., Engelmann, A., Weber, K., Horn, S., Müller, U., Arnold, M. A., Olson, E. N., & Stocking, C. (2008). The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate. Blood. https://doi.org/10.1182/blood-2007-10-116343

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.